Overview of organisational methods of primary cervical lesion screening programmes that use human papillomavirus testing

Author:

Marchadier Agathe1,Bezannier Laura2ORCID,Barré-Pierrel Stéphanie1ORCID,Manceau Antoine3,A Abadie Audrey3,Detournay Bruno2

Affiliation:

1. Institut National du Cancer, Boulogne Billancourt, France

2. Cemka, Bourg-la-Reine, France

3. PwC Advisory - Healthcare & Pharmaceuticals Life-Sciences, Neuilly-sur-Seine, France

Abstract

Many factors need to be considered when planning and managing a screening programme for the early detection of cervical cancer (CC). A non-systematic international review of the organisation of CC screening using high-risk human papillomavirus (HPV-HR) testing, aimed at identifying the organisational methods of these programmes, was conducted with a view to supporting the future of the French system in the context of the transition to HPV-HR testing. In countries where HPV testing has been implemented or planned, the initial reflection process has provided an opportunity to rethink the previous (cytological) screening organisation. Despite considerable differences between countries, a nationally or regionally centralised organisational model appears to be the preferred option in most countries. This model is based on a national/regional structure tasked with all invitations, reminders, follow-up and coordination, centralised laboratories integrating both biology and pathology laboratories, and a unified information system integrated with routine health management tools used by health practitioners and nurses. Besides quality considerations, grouped purchasing makes it possible to implement a public procurement policy that includes price negotiations with suppliers. Discussions around the introduction of HPV testing have resulted in most countries reviewing or creating information systems and quality assurance processes. While the WHO seems to recommend the systematic use of vaginal self-sampling, very few countries have considered this option. More and more countries are planning to implement vaginal self-sampling, but no clear organisational model has emerged from the countries where it has been implemented to date.

Publisher

SAGE Publications

Subject

Public Health, Environmental and Occupational Health,Health Policy

Reference38 articles.

1. Haute Autorité de Santé. Evaluation of human papillomavirus (HPV) tests for primary screening of precancerous and cancerous lesions of the cervix and the role of p16/Ki67 dual immunostaining. https://www.has-sante.fr/jcms/c_2806160/en/evaluation-of-human-papillomavirus-hpv-tests-for-primary-screening-of-precancerous-and-cancerous-lesions-of-the-cervix-and-the-role-of-p16/ki67-dual-immunostaining (accessed 18 July 2022).

2. World Health Organization. WHO guideline on self-care interventions for health and well-being. Geneva: World Health Organization, https://apps.who.int/iris/handle/10665/342741 (2021, accessed 18 July 2022).

3. HPV-based cervical cancer screening- facts, fiction, and misperceptions

4. Defining Optimal Triage Strategies for hrHPV Screen–Positive Women—An Evaluation of HPV 16/18 Genotyping, Cytology, and p16/Ki-67 Cytoimmunochemistry

5. Primary HPV-based cervical cancer screening in Europe: implementation status, challenges, and future plans

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3